-
公开(公告)号：US20140288060A1
公开(公告)日：2014-09-25
申请号：US14235755
申请日：2012-08-01
IPC分类号： A61K31/5415
CPC分类号： A61K31/5415 , A61K31/546 , C07D279/12
摘要： The invention relates to a compound for use in treating a cancer, wherein the cancer depends on the proteolytic activity of the MALT1 protease, and wherein the compound has the general formula (I) wherein X is N or C; Y is S, O, SO2, SO, NH, CO, CH2, CH═CH, CH2═CH2; ( )z is a C1-C5 linear or branched alkyl chain; A is NR3R4, or OR5, or HET; R1 and R2 in each occurrence are independently selected from —H, —CH3, —OH, —OCH3, —SCH3, —F, —Cl, —CF3, —NH2, and —COOH; R3, R4, and R5 are H, or C1-C5 linear or branched alkyl groups, and HET is a heterocyclic ring of 5, 6, or 7 members, wherein the ring atoms can be C, O, N, or S, the ring can be saturated or aromatic, and the ring can be substituted with H or C1-C5 linear or branched alkyl groups; or a pharmaceutically acceptable salt, prodrug, enantiomer, diastereomer, racemic mixture, crystalline form, amorphous form, unsolvated form or solvate of said compound. The compound of the invention may further be used in the treatment of MALT1-dependent immune diseases.
摘要翻译： 本发明涉及用于治疗癌症的化合物，其中所述癌症取决于MALT1蛋白酶的蛋白水解活性，并且其中所述化合物具有通式（I），其中X为N或C; Y是S，O，SO 2，SO，NH，CO，CH 2，CH = CH，CH 2 = CH 2; （）z为C1-C5直链或支链烷基链; A为NR3R4或OR5，或HET; R1和R2各自独立地选自-H，-CH 3，-OH，-OCH 3，-SCH 3，-F，-Cl，-CF 3，-NH 2和-COOH; R3，R4和R5是H或C1-C5直链或支链烷基，HET是5,6或7个成员的杂环，其中环原子可以是C，O，N或S， 环可以是饱和或芳族的，并且该环可以被H或C1-C5直链或支链烷基取代; 或药学上可接受的盐，前药，对映异构体，非对映体，外消旋混合物，结晶形式，无定形形式，所述化合物的非溶剂化形式或溶剂合物。 本发明的化合物还可用于治疗MALT1依赖性免疫疾病。
-
公开(公告)号：US08697854B2
公开(公告)日：2014-04-15
申请号：US13130665
申请日：2009-11-24
IPC分类号： C07K14/725 , C12N15/12
CPC分类号： C07K14/7051 , A61K35/17 , A61K38/1774 , C07K2319/40 , C12N15/85
摘要： The present invention is directed to a high affinity T cell receptor (TCR) against a tumor-associated antigen, an isolated nucleic acid molecule encoding same, a T cell expressing said TCR, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen.
摘要翻译： 本发明涉及针对肿瘤相关抗原的高亲和力T细胞受体（TCR），编码其的分离的核酸分子，表达所述TCR的T细胞和用于治疗涉及恶性疾病的药物组合物 表达所述肿瘤相关抗原的细胞。
-
公开(公告)号：US08486694B2
公开(公告)日：2013-07-16
申请号：US11990054
申请日：2006-08-04
IPC分类号： C12N5/10
CPC分类号： C07K14/705 , A61K2039/5154 , A61K2039/5156 , C12N5/0636 , C12N5/0639 , Y02A50/386 , Y02A50/412
摘要： The present invention is directed to a method of generating antigen specific T cells. Furthermore, the invention is directed to antigen specific T cells, isolated transgenic TCR's, pharmaceutical compositions containing same and their use in adoptive cell therapy. This invention in particular pertains to the use of cells co-expressing allogeneic MHC molecules and antigens to induce peptide-specific T cells from non-selected allogeneic T cell repertoires.
摘要翻译： 本发明涉及产生抗原特异性T细胞的方法。 此外，本发明涉及抗原特异性T细胞，分离的转基因TCR，含有它们的药物组合物及其在过继性细胞治疗中的用途。 本发明特别涉及共表达同种异体MHC分子和抗原的细胞用于从非选择的同种异体T细胞库中诱导肽特异性T细胞的用途。
-
4.发明授权Semi-allogenic anti-tumour vaccine with HLA haplo-identical antigen-presenting cells 有权具有HLA单倍体相同抗原呈递细胞的半同种异体抗肿瘤疫苗公开(公告)号：US08206701B2
公开(公告)日：2012-06-26
申请号：US10665111
申请日：2003-09-16
申请人： Dolores Schendel , Rudolf Wank
发明人： Dolores Schendel , Rudolf Wank
IPC分类号： A61K48/00
CPC分类号： A61K39/0011 , A61K48/00 , A61K2039/5154 , A61K2039/5156
摘要： The present invention relates to semi-allogeneic antigen-presenting cells into which proteins and/or peptides or RNA or DNA or cDNA, respectively, encoding said proteins and/or peptides which are overexpressed in tumor cells or which are derived from autologous tumor cells or different tumor cells or different tumor cell lines have been introduced. Furthermore the invention relates to methods for the generation of these semi-allogeneic antigen-presenting cells as well as to the use thereof in the treatment of tumor diseases.
摘要翻译： 本发明涉及半同种异体抗原呈递细胞，其中分别编码在肿瘤细胞中过表达或衍生自自体肿瘤细胞的所述蛋白质和/或肽的蛋白质和/或肽或RNA或DNA或cDNA 已经引入了不同的肿瘤细胞或不同的肿瘤细胞系。 此外，本发明涉及产生这些半同种异体抗原呈递细胞的方法以及其在治疗肿瘤疾病中的用途。
-
公开(公告)号：US20100189728A1
公开(公告)日：2010-07-29
申请号：US11990054
申请日：2006-08-04
CPC分类号： C07K14/705 , A61K2039/5154 , A61K2039/5156 , C12N5/0636 , C12N5/0639 , Y02A50/386 , Y02A50/412
摘要： The present invention is directed to a method of generating antigen specific T cells. Furthermore, the invention is directed to antigen specific T cells, isolated transgenic TCR's, pharmaceutical compositions containing same and their use in adoptive cell therapy. This invention in particular pertains to the use of cells co-expressing allogeneic MHC molecules and antigens to induce peptide-specific T cells from non-selected allogeneic T cell repertoires.
摘要翻译： 本发明涉及产生抗原特异性T细胞的方法。 此外，本发明涉及抗原特异性T细胞，分离的转基因TCR，含有它们的药物组合物及其在过继细胞治疗中的用途。 本发明特别涉及共表达同种异体MHC分子和抗原的细胞用于从非选择的同种异体T细胞库中诱导肽特异性T细胞的用途。
-
公开(公告)号：US09504692B2
公开(公告)日：2016-11-29
申请号：US14235755
申请日：2012-08-01
IPC分类号： A61K31/5415 , C07D279/12 , A61P19/02 , A61P17/06 , A61P25/28 , A61P35/00 , A61K31/546
CPC分类号： A61K31/5415 , A61K31/546 , C07D279/12
摘要： The invention relates to a compound for use in treating a cancer, wherein the cancer depends on the proteolytic activity of the MALT1 protease, and wherein the compound has the general formula (I) wherein X is N or C; Y is S, O, SO2, SO, NH, CO, CH2, CH═CH, or CH2—CH2; ( )z is a C1-C5 linear or branched alkyl chain; A is NR3R4, or OR5, or HET; R1 and R2 in each occurrence are independently selected from —H, —CH3, —OH, —OCH3, —SCH3, —F, —Cl, —CF3, —NH2, and —COOH; R3, R4, and R5 are H, or C1-C5 linear or branched alkyl groups, and HET is a heterocyclic ring of 5, 6, or 7 members, wherein the ring atoms can be C, O, N, or S, the ring can be saturated or aromatic, and the ring can be substituted with H or C1-C5 linear or branched alkyl groups; or a pharmaceutically acceptable salt, prodrug, enantiomer, diastereomer, racemic mixture, crystalline form, amorphous form, unsolvated form or solvate of said compound. The compound of the invention may further be used in the treatment of MALT1-dependent immune diseases.
-
7.发明授权Semi-allogenic anti-tumour vaccine with HLA haplo-identical antigen-presenting cells 有权具有HLA单倍体相同抗原呈递细胞的半同种异体抗肿瘤疫苗公开(公告)号：US09238063B2
公开(公告)日：2016-01-19
申请号：US13027827
申请日：2011-02-15
申请人： Dolores Schendel , Rudolf Wank
发明人： Dolores Schendel , Rudolf Wank
CPC分类号： A61K39/0011 , A61K48/00 , A61K2039/5154 , A61K2039/5156
摘要： The present invention relates to semi-allogeneic antigen-presenting cells into which proteins and/or peptides or RNA or DNA or cDNA, respectively, encoding said proteins and/or peptides which are overexpressed in tumor cells or which are derived from autologous tumor cells or different tumor cells or different tumor cell lines have been introduced. Furthermore the invention relates to methods for the generation of these semi-allogeneic antigen-presenting cells as well as to the use thereof in the treatment of tumor diseases.
摘要翻译： 本发明涉及半同种异体抗原呈递细胞，其中分别编码在肿瘤细胞中过表达或衍生自自体肿瘤细胞的所述蛋白质和/或肽的蛋白质和/或肽或RNA或DNA或cDNA 已经引入了不同的肿瘤细胞或不同的肿瘤细胞系。 此外，本发明涉及产生这些半同种异体抗原呈递细胞的方法以及其在治疗肿瘤疾病中的用途。
-
8.发明申请ATTACK OF TUMOR CELLS WITH MISSING, LOW OR ABERRANT MHC EXPRESSION BY COMBINING NON MHC-RESTRICTED T-CELLS/NK-CELLS AND MHC-RESTRICTED CELLS 有权通过组合非MHC限制性T细胞/ NK细胞和MHC限制性细胞，破坏肿瘤细胞，低或低表达MHC表达的肿瘤细胞公开(公告)号：US20100203086A1
公开(公告)日：2010-08-12
申请号：US12765234
申请日：2010-04-22
摘要： This invention is directed to therapeutic compositions containing non-MHC-restricted Tcells/NK-cells in combination with MHC-restricted T-cells and especially to therapeutic compositions, which comprise LAK cells. Furthermore, the present invention is directed to the use of the above combination in the treatment of tumors in humans, which tumors show a missing, low or aberrant expression of MHC class Ia or Ib molecules. By using the aforementioned compositions/combinations it is possible to provide a balanced selective pressure against emergence of tumor cell variants that would otherwise escape immune detection.
摘要翻译： 本发明涉及包含非限制性MHC限制性T细胞/ NK细胞与MHC限制性T细胞，特别是包含LAK细胞的治疗组合物的治疗组合物。 此外，本发明涉及上述组合在治疗人类肿瘤中的用途，其中肿瘤显示MHC Ia类或Ib类分子的缺失，低或异常表达。 通过使用上述组合物/组合，可能提供平衡的选择压力以抵抗否则将逃避免疫检测的肿瘤细胞变体的出现。
-
公开(公告)号：US20060171954A1
公开(公告)日：2006-08-03
申请号：US11397759
申请日：2006-04-05
申请人： Josef Endl , Peter Stahl , Winfried Albert , Guenther-Gerhard Jung , Dolores Schendel , Edgar Meinl , Klaus Dornmair
发明人： Josef Endl , Peter Stahl , Winfried Albert , Guenther-Gerhard Jung , Dolores Schendel , Edgar Meinl , Klaus Dornmair
摘要： The invention concerns autoreactive peptides, peptide-MHC complexes, T cell subpopulations that react thereto as well as diagnostic and therapeutic applications of these compounds.
摘要翻译： 本发明涉及自身反应肽，肽-MHC复合物，与其反应的T细胞亚群以及这些化合物的诊断和治疗应用。
-
10.发明授权Attack of tumor cells with missing, low or aberrant MHC expression by combining non MHC-restricted T-cells/NK-cells and MHC-restricted cells 有权通过组合非MHC限制性T细胞/ NK细胞和MHC限制性细胞来攻击具有缺失，低或异常MHC表达的肿瘤细胞公开(公告)号：US08142772B2
公开(公告)日：2012-03-27
申请号：US12765234
申请日：2010-04-22
摘要： This invention is directed to therapeutic compositions containing non-MHC-restricted Tcells/NK-cells in combination with MHC-restricted T-cells and especially to therapeutic compositions, which comprise LAK cells. Furthermore, the present invention is directed to the use of the above combination in the treatment of tumors in humans, which tumors show a missing, low or aberrant expression of MHC class Ia or Ib molecules. By using the aforementioned compositions/combinations it is possible to provide a balanced selective pressure against emergence of tumor cell variants that would otherwise escape immune detection.
摘要翻译： 本发明涉及包含非限制性MHC限制性T细胞/ NK细胞与MHC限制性T细胞，特别是包含LAK细胞的治疗组合物的治疗组合物。 此外，本发明涉及上述组合在治疗人类肿瘤中的用途，其中肿瘤显示MHC Ia类或Ib类分子的缺失，低或异常表达。 通过使用上述组合物/组合，可能提供平衡的选择压力以抵抗否则将逃避免疫检测的肿瘤细胞变体的出现。
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.019 秒)
